Related Experiment Videos
Invasive Scopulariopsis in the immunocompromised host
J P Neglia1, D D Hurd, P Ferrieri
1Department of Pediatrics, University of Minnesota, Minneapolis.
Abstract:
Opportunistic infections with fungal organisms have been well described in patients undergoing intensive chemotherapy and bone marrow transplantation. In two patients, invasive infections with the saprophyte Scopulariopsis developed either following intensive chemotherapy or bone marrow transplant. Fungal disease persisted in both patients despite resection of the primary focus and prolonged treatment with the usual antifungal agents, and contributed to the death of one patient.
Insights
Invasive fungal infections caused by Scopulariopsis can occur after intensive chemotherapy or bone marrow transplant. These infections are difficult to treat and can be fatal, even with standard antifungal therapies.
Area of Science:
- Mycology
- Infectious Diseases
- Hematology
Background:
- Opportunistic fungal infections are a known risk for immunocompromised patients, particularly those undergoing intensive chemotherapy and bone marrow transplantation.
- Standard antifungal treatments are often effective against common fungal pathogens in these patient populations.
Observation:
- Two cases of invasive infections caused by the saprophytic fungus Scopulariopsis were observed in patients.
- These infections occurred in the context of intensive chemotherapy or bone marrow transplantation.
Findings:
- The fungal disease caused by Scopulariopsis persisted in both patients despite surgical removal of the infected area and extended treatment with conventional antifungal agents.
- Invasive Scopulariopsis infection contributed to the mortality of one of the two patients.
Implications:
- Scopulariopsis should be considered as a potential pathogen in invasive fungal infections in immunocompromised patients.
- Current antifungal strategies may be insufficient for treating invasive Scopulariopsis infections, necessitating further research into alternative or novel therapeutic approaches.